secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001739104-24-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q2 revenue $1.184B, adjusted EPS $0.30; raises full-year revenue guidance
--------------------------------------------------------------------------------

- Q2 revenue $1.184B (+12% reported, +13% CC); pet health $579M (+12%), farm animal $594M (+13%).
- Adjusted EPS $0.30 (+67% YoY); adjusted EBITDA $275M (23.2% margin) vs $222M (21.0%).
- Full year organic CC revenue growth guidance raised to 3%-4% (from 2%-3%); adjusted EPS maintained at $0.88-$0.96.
- Aqua divestiture closed July 9, ~$1.2B proceeds used to pay down debt; gross debt reduced to ~$4.5B; net leverage 5.6x.
- Zenrelia FDA final 60-day review; approval expected late Sept. Bovaer commercial activities underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000025/0001739104-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000025/elan-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001739104-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer